Tandem Isotope Therapy with ²²⁵Ac- and ¹⁷⁷Lu-PSMA-617 in a Murine Model of Prostate Cancer.

ABSTRACT: Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is a promising option for metastatic castration-resistant prostate cancer. Clinical experience using ¹⁷⁷Lu or ²²⁵Ac has demonstrated encouraging treatment responses; however, responses are not durable. Dual-isotope combinations, or "tandem" approaches, may improve tolerability while retaining a high tumor dose. In this study, we directly compared α- versus β-particle treatment, as well as a combination thereof, at different stages of disease in a murine model of disseminated prostate cancer. Methods: First, to determine comparable injected activities from ¹⁷⁷Lu- and ²²⁵Ac-PSMA-617, ex vivo biodistribution studies were performed at 5 time points after treatment of C4-2

SUBMITTER: Meyer C 

PROVIDER: S-EPMC10626377 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature